A Controlled Clinical Trial to Train the Aiberry AI Depression Detection Platform

Sponsor

Aiberry, Inc (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT04994899

Collaborator

(none)

1,000

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This controlled, multicenter trial will train and validate the Aiberry platform's ability to detect depression in a diverse patient population. Up to 10 sites in the United States will participate in this protocol. Adults and children may participate (ages 13-79). A total of 1,000 eligible subjects will complete depression screenings and an Aiberry video recorded interview during 1 clinic visit. Analysis will be stratified by depression diagnosis status, race/ethnicity, and age. Subjects will participate in a baseline questionnaire to collect demographic information and health history.

Condition or Disease	Intervention/Treatment	Phase
Depression	Other: Aiberry Depression Detection AI Platform

Study Design

Study Type:

Observational

Anticipated Enrollment :

1000 participants

Observational Model:

Other

Time Perspective:

Prospective

Official Title:

A Controlled Clinical Trial to Train the Aiberry AI Depression Detection Platform on a Diverse Set of Population in a Live Setting and Further Enhance the Detection Accuracy

Anticipated Study Start Date :

Sep 1, 2021

Anticipated Primary Completion Date :

Aug 1, 2022

Anticipated Study Completion Date :

Aug 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Interview & Depression Screening	Other: Aiberry Depression Detection AI Platform Aiberry is a next-generation artificial intelligence (AI) company that leverages deep tech to screen for mental health and brain-related disorders.

Arm

Intervention/Treatment

Interview & Depression Screening

Other: Aiberry Depression Detection AI Platform

Aiberry is a next-generation artificial intelligence (AI) company that leverages deep tech to screen for mental health and brain-related disorders.

Outcome Measures

Primary Outcome Measures

Train the Aiberry platform on a diverse patient population [2021-2022]

Secondary Outcome Measures

Predict depression at higher degree of accuracy than standard paper-based screening instruments [2021-2022]
Test, train and implement the Aiberry platform in a live environment [2021-2022]

Eligibility Criteria

Criteria

Ages Eligible for Study:

13 Years to 79 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Age 13 to 79 years old
English-speaking

Exclusion Criteria:

Previous participant in the study
Individuals unable to verbally respond to standardized questions
Individuals unable to participate in a virtual visit as they do not have the right hardware (phone/laptop) or no internet connectivity
Individuals unable to provide consent

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Aiberry, Inc

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Aiberry, Inc

ClinicalTrials.gov Identifier:

NCT04994899

Other Study ID Numbers:

Aiberry Depression

First Posted:

Aug 6, 2021

Last Update Posted:

Aug 6, 2021

Last Verified:

Jul 1, 2021

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Depression

Depressive Disorder

Study Results

No Results Posted as of Aug 6, 2021